Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) will host a conference call on Thursday, November 6, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide a corporate update.

Interested parties may join the live webcast via the company's investor relations site and are advised to log in about 15 minutes before the start. A recording will be available on the investor relations website shortly after the event.

News Market Reaction – IVVD

-13.04%

10 alerts

-13.04% Session close to close

-26.1% Trough in 34 hr 20 min

$377.36M Market Cap

0.6x Rel. Volume

In the Nov 4 session, IVVD declined 13.04%, reflecting a significant negative market reaction. Argus tracked a trough of -26.1% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update.

Interested parties may join the live webcast by visiting this link and are advised to log in approximately 15 minutes prior to the start of the call. A recording of the webcast will be available on the company’s investor relations website shortly after the event.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Contacts:
Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

When is Invivyd's (IVVD) Q3 2025 earnings call scheduled?

The call is scheduled for Thursday, November 6, 2025 at 8:30 a.m. ET.

How can I access the Invivyd (IVVD) November 6, 2025 webcast?

Join the live webcast via Invivyd's investor relations website; log in about 15 minutes early.

Will Invivyd (IVVD) provide a replay of the Q3 2025 call?

Yes. A recording of the webcast will be posted on the company's investor relations website shortly after the event.

What will Invivyd (IVVD) discuss on the November 6, 2025 call?

Management will discuss third quarter 2025 financial results and provide a corporate update.

Do I need to register before joining the Invivyd (IVVD) webcast on November 6, 2025?

Attendees are advised to access the investor relations webcast link and log in approximately 15 minutes before the call.

Where can investors find the Q3 2025 presentation materials for Invivyd (IVVD)?

Presentation materials and the webcast recording will be available on Invivyd's investor relations website after the event.